RNAi Matures in 2013 amid New Delivery Approaches, Renewed Interest by Big Pharma | GenomeWeb

For RNAi, 2013 proved to be a year largely marked by incremental successes that, while not always the most attention grabbing, reflect the maturity of the gene-silencing technology and have helped it begin to reignite the interest of big pharma in RNA therapeutics.

It was during the past year that RNAi — indeed, RNA therapeutics in general — "have come of age," Regulus Therapeutics CEO Kleanthis Xanthopoulos told Gene Silencing News. "There is no longer skepticism about whether the … approach works."

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

University of Wisconsin researchers uncover a mutation linked to Mauriac syndrome, which affects some children with type 1 diabetes.

Theranos has hired executives to oversee compliance and regulatory issues, the Wall Street Journal reports.

Chinese researchers to embark on a trial using a CRISPR/Cas9-based immunotherapy next month, Nature News reports.

In Science this week: new chromatin imaging approach, and more.